Table 3.
Inhibition of orthopoxvirus growth by antiviral compounds
| Drug target | VAR-BSH |
VAR-YAM |
VAR-GAR |
MPX |
CPX |
VAC |
Cytotoxicity |
|||||||||||||||||||||
| Vero | LLC-MK2 | Vero | LLC-MK2 | Vero | LLC-MK2 | Vero | LLC-MK2 | Vero | LLC-MK2 | Vero | LLC-MK2 | Vero | LLC-MK2 | |||||||||||||||
| DNA polymerase | ||||||||||||||||||||||||||||
| bis-POM-PMEA | 84.2 | >100 | >100 | >100 | 90.0 | 85.0 | >100 | >100 | 75.5 | 86.0 | 44.0 | 66.2 | >100 | >100 | ||||||||||||||
| HPMPA | 12.6 | 6.1 | 11.4 | 6.8 | 6.6 | 4.6 | 10.9 | 9.2 | 8.4 | 7.7 | 8.1 | 8.0 | >100 | >100 | ||||||||||||||
| Cidofovir | 9.5 | 3.2 | 12.1 | 2.7 | 4.5 | 2.5 | 6.7 | 3.7 | 7.5 | 1.2 | 8.1 | 4.3 | >100 | >100 | ||||||||||||||
| cHPMPC | 25.3 | 20.3 | 28.2 | 6.1 | 7.9 | 5.9 | 12.3 | 3.4 | 26.9 | >100 | 18.1 | 4.4 | 80.0 | >100 | ||||||||||||||
| IMP dehydrogenase | ||||||||||||||||||||||||||||
| Ribavirin | 18.4 | 2.1 | 15.8 | 3.4 | 17.0 | 3.6 | 5.9 | 4.1 | 30.6 | 10.6 | >100 | 23.9 | >100 | >100 | ||||||||||||||
| Tiazofurin | 22.6 | 5.5 | 21.4 | 3.9 | 19.8 | 6.1 | 20.0 | 5.2 | 34.6 | 11.0 | >100 | 33.3 | 90.0 | >100 | ||||||||||||||
| SAH hydrolase | ||||||||||||||||||||||||||||
| C-ca3-Ado | 1.2 | 1.6 | 5.3 | 1.4 | 1.6 | 4.4 | 0.4 | 0.8 | >100 | 25.2 | 1.2 | 3.4 | >100 | >100 | ||||||||||||||
| C3-Npc A | 0.03 | 0.47 | 0.04 | 0.24 | 0.04 | 0.45 | 0.01 | 0.05 | >100 | >100 | 0.02 | 0.05 | >100 | >100 | ||||||||||||||
| Other | ||||||||||||||||||||||||||||
| DFBA | 0.16 | >100 | 0.14 | >100 | 0.14 | >100 | 0.95 | >100 | 0.71 | >100 | 1.18 | >100 | 75.0 | >100 | ||||||||||||||
| Methisazone | 34.6 | 41.2 | 39.0 | 43.3 | 21.6 | 44.1 | 66.2 | 80.4 | 49.2 | 45.2 | 45.8 | 52.0 | >100 | >100 | ||||||||||||||
Inhibition of orthopoxvirus replication in Vero and cells by a series of antiviral compounds, as measured by neutral red uptake assay. Values are IC50 for each virus or TC50 for cytotoxicity (μg/ml).